1. 10P Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC. (15th December 2019) Authors: Mazzaschi, G; Minari, R; Ferri, V; Gnetti, L; Bersanelli, M; Cavazzoni, A; Bordi, P; Squadrilli, A; Buti, S; Cosenza, A; Ferri, L; Rapacchi, E; Petronini, P G; Missale, G; Quaini, F; Tiseo, M Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 891PCorrelation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study. (23rd October 2018) Authors: Vitale, M G; Pipitone, S; Scagliarini, S; Zucali, P A; Galli, L; Rossetti, S; Caserta, C; Iacovelli, R; Masini, C; Ficorella, C; Di Girolamo, S; Buti, S; Benedetti, B; Santoni, M; Porta, C; Bracarda, S; Baldessari, C; Giaquinta, S; Cascinu, S; Sabbatini, R Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. (28th March 2018) Authors: Buti, S; Puligandla, M; Bersanelli, M; DiPaola, R S; Manola, J; Taguchi, S; Haas, N B Journal: Annals of oncology Issue: Volume 29:Number 7(2018) Page Start: 1604 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗